Abstract
OBJECTIVES: To propose the benefit of antifibrotic agent, nintedanib, in the treatment of lung fibrosis from SARS-CoV-2 Coronavirus 2019 (COVID-19) pneumonia, based on experience at Bangkok Hospital Headquarters, Bangkok, Thailand. MATERIALS AND METHODS: Data from patients who developed lung fibrosis post COVID-19 pneumonia during 2020-2022 at our institute, all developed severe pneumonia, was analyzed, including clinical signs and symptoms, imaging findings, O2 saturation: at room air and during 6 minutes’ walk, and response to treatment. RESULTS: Among 10 patients with COVID-19 lung fibrosis who received steroids, remdesivir and nintedanib; 2 patients (20%) expired, 7 patients (70%) were back to normal within 3 months, and 1 patient (10%) was able to walk with oxygen 2 liter per minute (LPM) after 7 months. CONCLUSION: An antifibrotic agent, such as nintedanib, could improve lung fibrosis from COVID-19 pneumonia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.